PMID- 21941211
OWN - NLM
STAT- MEDLINE
DCOM- 20120308
LR  - 20221207
IS  - 1708-8267 (Electronic)
IS  - 1081-5589 (Linking)
VI  - 59
IP  - 8
DP  - 2011 Dec
TI  - Levels of soluble advanced glycation end product-receptors and other soluble 
      serum markers as indicators of diabetic neuropathy in the foot.
PG  - 1233-8
LID - 10.2130/JIM.0b013e318231db64 [doi]
AB  - OBJECTIVE: Advanced glycation end products (AGEs) and the interaction with their 
      receptors (RAGE) play an important role in the pathogenesis of diabetic foot (DF) 
      associated with diabetic neuropathy. Our study examined the association between 
      asymmetric dimethyl arginine (ADMA), fructosamine, nitric oxide (NO), and soluble 
      (s) RAGE levels in serum of diabetic patients with and without neuropathy. 
      METHODS: Circulating levels of ADMA, fructosamine, NO, and sRAGE, estimated 
      either chemically or by enzyme-linked immunosorbent assay, were examined in 60 
      type 2 diabetes mellitus (T2DM) overweight/obese (body mass index, 30.5 +/- 1.5 
      kg/m(2)) male patients and 20 age-matched (55 +/- 3 years) obese healthy subjects as 
      control group. The T2DM subjects were categorized as patients without DF (n = 
      30), and the remaining were patients with DF associated with neuropathy. RESULTS: 
      First sRAGE levels were significantly increased in T2DM patients without DF in 
      comparison to healthy controls (1656.6 [1198.8-2065.4] vs 1111.7 [909-1605.3] 
      pg/mL, respectively; P < 0.05). However, in the DF group (1049.6 [783.7-1221.8] 
      pg/mL), its level decreased significantly in comparison to both groups (P < 
      0.05). However, ADMA and fructosamine were significantly higher in diabetic 
      patients with DF than both T2DM without DF and healthy controls. Moreover, NO was 
      significantly lower in DF than in diabetic patients without DF and controls (5 +/- 
      0.4 and 8 +/- 0.4 vs 42 +/- 2.5 mumol/L, respectively; P < 0.05). Finally, sRAGE 
      levels were significantly correlated with ADMA, fructosamine, and NO. 
      CONCLUSIONS: Soluble forms of the receptor for advanced glycation end product 
      could be an endogenous protection factor against occurrence of DF, hence may be 
      of therapeutic value in the treatment of DF.
FAU - El-Mesallamy, Hala O
AU  - El-Mesallamy HO
AD  - Biochemistry Department, Faculty of Pharmacy, Ain-Shams University, Cairo, Egypt.
FAU - Hamdy, Nadia M
AU  - Hamdy NM
FAU - Ezzat, Omnia A
AU  - Ezzat OA
FAU - Reda, Ahmed M
AU  - Reda AM
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Investig Med
JT  - Journal of investigative medicine : the official publication of the American 
      Federation for Clinical Research
JID - 9501229
RN  - 0 (Biomarkers)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Receptor for Advanced Glycation End Products)
RN  - 0 (Receptors, Immunologic)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 63CV1GEK3Y (N,N-dimethylarginine)
RN  - 94ZLA3W45F (Arginine)
SB  - IM
MH  - Aged
MH  - Arginine/analogs & derivatives/blood
MH  - Biomarkers/blood
MH  - Diabetes Mellitus, Type 2/blood/complications
MH  - Diabetic Foot/*blood/complications
MH  - Diabetic Neuropathies/*blood/complications
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nitric Oxide/blood
MH  - Receptor for Advanced Glycation End Products
MH  - Receptors, Immunologic/*blood
MH  - Solubility
EDAT- 2011/09/24 06:00
MHDA- 2012/03/09 06:00
CRDT- 2011/09/24 06:00
PHST- 2011/09/24 06:00 [entrez]
PHST- 2011/09/24 06:00 [pubmed]
PHST- 2012/03/09 06:00 [medline]
AID - 10.2130/JIM.0b013e318231db64 [doi]
PST - ppublish
SO  - J Investig Med. 2011 Dec;59(8):1233-8. doi: 10.2130/JIM.0b013e318231db64.